RNF168 promotes chronic colitis through ANXA7-mediated autophagy and NLRP3-driven pyroptosis.

Area of Science:

• Gastroenterology
• Molecular Biology
• Immunology

Background:

• Crohn's disease (CD) involves inflammation and intestinal barrier disruption.
• The molecular mechanisms underlying CD progression require further elucidation.

Purpose of the Study:

• Investigate the roles of ANXA7 and RNF168 in CD.
• Elucidate the regulatory axis involving ELK1, RNF168, and ANXA7 in CD pathogenesis.
• Explore therapeutic strategies targeting this axis.

Main Methods:

• Analysis of human colon tissues from CD patients.
• In vitro studies using cell lines with ANXA7 manipulation.
• Protein interaction studies (Co-IP, mass spectrometry, ubiquitination assays).
• In vivo models including knockout mice and TNBS-induced colitis.
• Organoid cultures.

Main Results:

• ANXA7 expression is reduced in inflamed CD tissues.
• RNF168 promotes ANXA7 ubiquitination and degradation, suppressing autophagy and enhancing pyroptosis.
• ELK1 upregulates RNF168, forming a regulatory axis.
• Targeting RNF168 and ANXA7 demonstrated therapeutic potential in vivo.

Conclusions:

• A novel mechanistic model for CD progression involving ELK1-RNF168-ANXA7 axis is proposed.
• This axis drives inflammation, autophagy suppression, and pyroptosis, disrupting the intestinal barrier.
• The RNF168-ANXA7 pathway represents a potential therapeutic target for Crohn's disease.